Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

Employees

Sector

Pharmaceuticals

Calendar

09-30 Earnings release - Q2 2026

More about the company

Market Cap	260M 321M 276M 237M 442M 30.43B 445M 3.08B 1.19B 15.56B 1.21B 1.18B 49.5B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	287M 355M 305M 262M 489M 33.68B 492M 3.4B 1.32B 17.21B 1.33B 1.3B 54.78B	EV / Sales 2026 *	3.03x	EV / Sales 2027 *	2.43x
Free-Float	81.55%	Yield 2026 *	-	Yield 2027 *	-

07-13	Santhera Pharmaceuticals and Biomedica Expand AGAMREE Distribution Agreement Across Central Asia and the Caucasus	CI
07-13	Santhera Pharmaceuticals Extends Agamree Distribution Agreement with Biomedica	MT
07-01	Santhera Says Early Trial Backs Agamree for Chronic Inflammatory Rare Diseases	MT
07-01	Santhera Pharmaceuticals Notes Topline Results from Catalyst Pharmaceuticals Phase 1 Clinical Study of AGAMREE	CI
06-02	Santhera Pharmaceuticals Secures Orphan Drug, Fast Track Designations for Agamree in South Korea	MT
05-26	Santhera Pharmaceuticals Holding Ag Approves Board and Committee Appointments	CI
05-01	Santhera Pharmaceuticals Holding AG, 2025 Earnings Call, Apr 28, 2026
04-28	Italy Approves Reimbursement of Santhera's Duchenne Muscular Dystrophy Drug	MT
04-28	Santhera Pharmaceuticals' FY25 Net Loss Widens; Revenue Up	MT
04-28	Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025	DJ
04-28	Santhera Pharmaceuticals Announces Reimbursement Approval for AGAMREE in Italy	CI
04-28	Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-27	Swiss Market Index Closes Little Changed; Santhera Shares Jump	MT

07-13	Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus	AQ
07-01	Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®	AQ
06-02	Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea	AQ
05-26	Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting	AQ
05-05	Santhera Publishes Agenda for its Annual General Meeting	AQ

07-13	Santhera étend son accord avec Biomedica pour Agamree
07-13	Santhera erweitert Vereinbarung mit Biomedica für Agamree in Zentralasien
07-01	Santhera: Agamree hat entzündungshemmende Wirkung ohne immunsuppressive Effekte
07-01	Santhera: Agamree présente un effet anti-inflammatoire
06-02	Santhera obtient une procédure accélérée pour Agamree en Corée du Sud

Manager	Title	Age	Since
Orlando Oliveira CEO	Chief Executive Officer	50	14/07/2026
Catherine Isted DFI	Director of Finance/CFO	51	23/02/2025
Marc Schrader COO	Chief Operating Officer	55	31/08/2022

Santhera Pharmaceuticals Holding AG Share Price Xetra

Stocks

S3F

CH0027148649

Pharmaceuticals

Valuation : Santhera Pharmaceuticals Holding AG

Latest news : Santhera Pharmaceuticals Holding AG

Last Transcript : Santhera Pharmaceuticals Holding AG

Press Releases : Santhera Pharmaceuticals Holding AG

News in other languages : Santhera Pharmaceuticals Holding AG

Managers and Directors : Santhera Pharmaceuticals Holding AG

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Thomas Meier CHM	Chairman	64	29/06/2022
Philipp Gutzwiller BRD	Director/Board Member	58	03/04/2017
Bradley Meyer BRD	Director/Board Member	47	26/06/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SANTHERA PHARMACEUTICALS HOLDING AG	-.--%	-0.62%	-	-	321M
MERCK & CO., INC.	-0.14%	-1.97%	+75.69%	+36.88%	366B
MERCK KGAA	-1.60%	-5.21%	+21.30%	-19.58%	68.06B
HALOZYME THERAPEUTICS, INC.	-0.22%	-1.30%	+42.28%	+188.63%	12.29B
KYOWA KIRIN CO., LTD.	-5.88%	-6.95%	-13.33%	-15.00%	8.02B
SK BIOPHARMACEUTICALS CO., LTD.	-2.12%	-6.52%	-24.02%	+1.59%	4.86B
YUHAN CORPORATION	-1.98%	-4.35%	-35.00%	+13.77%	4.4B
BETTA PHARMACEUTICALS CO., LTD.	-0.66%	-3.31%	-33.17%	-6.25%	3.01B
SUPERNUS PHARMACEUTICALS, INC.	-0.33%	-4.29%	-8.45%	+41.50%	2.47B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	0.00%	-3.14%	-26.21%	-18.41%	1.99B
Average	-1.28%	-2.22%	-0.10%	+24.79%	52.37B
Weighted average by Cap.	-0.51%	+0.33%	+61.83%	+30.74%

	2026 *	2027 *
Net sales	94.7M 117M 101M 86.42M 161M 11.1B 162M 1.12B 434M 5.67B 440M 430M 18.05B	116M 143M 123M 105M 197M 13.54B 198M 1.37B 530M 6.92B 536M 525M 22.03B
Net income	-	-
Net Debt	27.7M 34.24M 29.44M 25.28M 47.17M 3.25B 47.42M 328M 127M 1.66B 129M 126M 5.28B	21.4M 26.46M 22.75M 19.53M 36.45M 2.51B 36.63M 254M 98.1M 1.28B 99.34M 97.18M 4.08B